Jubilant Life Sciences has reported results for first quarter ended June 30, 2012.
The company has reported a loss of Rs 73.60 crore for the quarter under review as compared to net profit of Rs 53.89 crore for the same quarter in the previous year. The total income from operation of the company has increased by 19.85% at Rs 742.57 crore for Q1FY13 as compared Rs 619.56 crore for the corresponding quarter previous year.
On consolidated basis, the group’s net profit after taxes, minority interest and share of profit of associates tumbled by 93.50% to Rs 5.01 crore for the Q1FY13 as compared to Rs 77.12 crore in Q1 FY12. However, the total income rose 30.51% to Rs 1240.30 crore in the quarter under review as compared to Rs 950.32 crore in the corresponding previous quarter.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: